A Phase 1/2 interventional study of Tradipitant and Placebo in Healthy Volunteer, sponsored by Vanda Pharmaceuticals. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-04-16.
Sponsored by Vanda Pharmaceuticals · Phase 1/2, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
To evaluate the effects of tradipitant relative to placebo on satiation, gastric volume, gastric accommodation, and gastric emptying in healthy volunteers.
Vanda Pharmaceuticals is the lead sponsor of 82 studies on the registry; 17 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 22 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Oral Capsule
Drug: Tradipitant
Oral Capsule
Drug: Placebo
Tradipitant Capsule
Placebo Capsule
Fasting Gastric Volume as Measured by Single Photon Emission Computed Tomography (SPECT)
Fasting Gastric volume
Time frame: 9 Days
Accommodation Volume as Measured by SPECT
Gastric Accommodation post 300mL Ensure
Time frame: 9 Days
Satiation Expressed as Volume to Fullness as Measured by Satiation Test
Time frame: 9 Days
Gastric Emptying Half-time of Solids as Measured by Scintigraphy
Gastric Emptying Solids, T50%, Min
Time frame: 9 Days
| Milestone | Tradipitant | Placebo |
|---|---|---|
| Started | 13 | 14 |
| Completed | 11 | 13 |
| Not completed | 2 | 1 |
| Withdrew: Withdrawal by subject | 2 | 1 |
Fasting Gastric volume
| mL | Tradipitant | Placebo |
|---|---|---|
| Fasting Gastric Volume as Measured by Single Photon Emission Computed Tomography (SPECT) | 178.8 (158.0 to 217.0) | 191.1 (169.2 to 216.9) |
Gastric Accommodation post 300mL Ensure
| mL | Tradipitant | Placebo |
|---|---|---|
| Accommodation Volume as Measured by SPECT | 423.8 (358.5 to 484.1) | 411.0 (358.3 to 476.3) |
| mL | Tradipitant | Placebo |
|---|---|---|
| Satiation Expressed as Volume to Fullness as Measured by Satiation Test | 592.5 (474.0 to 829.5) | 711.0 (474.0 to 948.0) |
Gastric Emptying Solids, T50%, Min
| minutes | Tradipitant | Placebo |
|---|---|---|
| Gastric Emptying Half-time of Solids as Measured by Scintigraphy | 137.0 (106.8 to 145.0) | 134.0 (125.3 to 141.7) |
Collected over 9 days. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tradipitant | 0/13 (0%) | 0/13 (0%) | 4/13 (30.8%) |
| Placebo | 0/14 (0%) | 0/14 (0%) | 4/14 (28.6%) |
| Event | Tradipitant | Placebo |
|---|---|---|
| fatigueGeneral disorders | 2/13 | 1/14 |
| somnolenceNervous system disorders | 2/13 | 1/14 |
| peripheral swellingGeneral disorders | 1/13 | 0/14 |
| diarrheaGastrointestinal disorders | 1/13 | 0/14 |
| AcneSkin and subcutaneous tissue disorders | 1/13 | 0/14 |
| headacheNervous system disorders | 1/13 | 1/14 |
| disturbance in attentionNervous system disorders | 1/13 | 0/14 |
| dizziness posturalNervous system disorders | 1/13 | 0/14 |
| restless leg syndromeNervous system disorders | 1/13 | 0/14 |
| depressed moodPsychiatric disorders | 1/13 | 0/14 |
| Age, Continuous(Years) | Tradipitant | Placebo | Total |
|---|---|---|---|
| Mean | 32.5 ± 9.61 | 34.9 ± 10.70 | 33.7 ± 10.07 |
| Sex: Female, Male(Participants) | Tradipitant | Placebo | Total |
|---|---|---|---|
| Female | 7 | 6 | 13 |
| Male | 6 | 8 | 14 |
| Ethnicity (NIH/OMB)(Participants) | Tradipitant | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 2 | 3 |
| Not Hispanic or Latino | 12 | 12 | 24 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Tradipitant | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 3 | 4 | 7 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 6 | 7 | 13 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 4 | 3 | 7 |
| Region of Enrollment(participants) | Tradipitant | Placebo | Total |
|---|---|---|---|
| United States | 13 | 14 | 27 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Feb 2021 to primary completion in Sep 2021, 7 months.
Results were first posted in Apr 2024, 2 years 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tradipitant